Richemont’s $1B De Beers Play Is a Bet Against Lab-Grown Diamonds
De Beers lost $511 million last year, yet Cartier owner Richemont may want in. That is either very smart vertical integration or an expensive attempt to save a story customers are abandoning.
De Beers lost $511 million in 2025. Now Richemont, the owner of Cartier and Van Cleef & Arpels, is reportedly considering joining a consortium to buy it.
That sounds mad until you understand what is really being bought: not a mine, but control over the story that makes a rock pulled from the ground worth vastly more than one grown in a lab.
This is not a normal acquisition
Richemont and US jewellery retailer Signet are reportedly in talks to join the Global Diamond Consortium, a bidder led by former De Beers chief executive Gareth Penny. The consortium is pursuing Anglo American’s 85% stake in De Beers; Botswana owns the remaining 15%. The diamond business is being valued at roughly $1 billion.
Important point: this is not a signed deal. It is a live conversation around a consortium, and either Richemont or Signet could still stay out. But the direction matters more than the paperwork at this stage. Two businesses that sell diamond jewellery to consumers may be preparing to put money behind the company that digs up, sorts, markets and legitimises the stones in the first place. ([news.bloomberglaw.com](https://news.bloomberglaw.com/mergers-and-acquisitions/richemont-and-signet-said-in-talks-to-join-bidder-for-de-beers?utm_source=openai))
Most people will look at the $1 billion valuation and say De Beers is cheap. That is lazy analysis.
Cheap compared with what? Compared with its history? Sure. Compared with the old world where De Beers had enormous power over supply, pricing and consumer desire? Absolutely. But a struggling asset is not automatically a bargain. Sometimes it is simply a business whose economics have changed faster than its owners can admit.
De Beers generated $3.493 billion in 2025 revenue, but its underlying EBITDA swung to a $511 million loss, from a $25 million loss the year before. Its average realised price fell 7% to $142 per carat. Once you include stock-rebalancing sales—moving lower-demand inventory at lower effective prices—the relevant price-index decline was 25%. That is not a rough patch. That is a flashing dashboard. ([debeersgroup.com](https://www.debeersgroup.com/news-insights/latest-group-news/2026/preliminary-financial-results-for-2025?utm_source=openai))
Anglo American is selling a problem. Richemont may be buying an insurance policy.
Anglo American wants out because De Beers no longer fits the mining giant’s simplified future. Anglo is concentrating on copper, premium iron ore and other assets where the economics are clearer and the strategic logic is less romantic. It recorded a $2.3 billion pre-tax impairment related to De Beers in its 2025 results, and says the sale process is advancing. ([angloamerican.com](https://www.angloamerican.com/media/press-releases/2026/20-02-2026?utm_source=openai))
That is the seller’s logic.
Richemont’s logic would be very different. It is not trying to become a better miner. It is trying to defend the high-end jewellery category that makes it serious money.
Richemont’s Jewellery Maisons produced €16.5 billion of FY2026 sales and a 30.5% operating margin. The group finished March with €8.5 billion of net cash. So, yes, it has the balance-sheet capacity to participate in a $1 billion consortium deal without putting Cartier’s future on the roulette table. ([richemont.com](https://www.richemont.com/news-media/press-releases-news/richemont-delivers-strong-sales-growth-and-solid-results-for-the-year-ended-31-march-2026/?utm_source=openai))
But this would not be about getting a cheaper parcel of rough diamonds. Cartier does not win because it shaves a few dollars off its input cost. Cartier wins because customers believe the finished piece is rare, beautiful, trustworthy and worth handing down.
Lab-grown diamonds attack that belief from two sides.
First, they offer a visually similar product at a much lower price. Second, they force the natural-diamond industry to answer an uncomfortable question: if the stone looks the same and costs far less, what exactly am I paying for?
The old answer was scarcity. The better answer now has to be provenance, craftsmanship, design, heritage and emotional significance. That is a branding job, not a geology job.
The overlooked angle: the buyers would be buying demand, not supply
Here is the bit most deal coverage misses: De Beers does not need more capital just to pull rocks out of the earth. It needs a credible coalition that can rebuild demand for natural diamonds.
A consortium involving Richemont and Signet would bring something a pure private-equity buyer cannot: direct exposure to the consumer at opposite ends of the jewellery market. Richemont understands luxury aspiration. Signet understands mass-market jewellery retail in the United States. Gareth Penny understands De Beers. Botswana understands that diamonds are not merely an asset class; they are tied to national revenue, jobs and political legitimacy.
That combination could be useful. It could also be a committee from hell.
Consortium deals are often praised because they spread risk. True. They also spread conviction, slow decisions and give every participant a reason to protect its own patch. A luxury house wants prestige. A public retailer wants volume. A government wants employment and revenue. A former mining executive wants operational recovery. Those goals overlap, but they are not the same thing.
The sensible structure would be to keep De Beers operationally independent while using the shareholders to do what De Beers cannot do alone: create a properly funded, category-wide case for natural diamonds, with traceability that is credible rather than marketing fluff.
That means better proof of origin, cleaner separation between natural and lab-grown stones, and a brutally clear consumer message. Not “natural is better because we said so.” That ship has sailed. The message has to be: natural diamonds are a distinct luxury product with a documented history and limited supply; lab-grown diamonds are a different product with a different value proposition.
Trying to pretend the two products are identical would be stupid. They are not identical economically, culturally or emotionally. Trying to pretend lab-grown stones do not exist would be even stupider.
The contrarian case: do not confuse vertical integration with intelligence
Founders love the phrase “own the supply chain.” It sounds tough. It also causes plenty of people to buy businesses they have no business owning.
Vertical integration works when owning the upstream asset gives you one of three things: materially better economics, reliable access to a constrained input, or control over something the customer genuinely values.
If none of those are true, you have not built a moat. You have bought yourself another management problem.
For Richemont, the first two arguments are weak on their own. De Beers is loss-making, and Cartier is not short of diamonds in the way a semiconductor maker might be short of chips. The third argument is the only one that matters: can involvement in De Beers help protect consumer trust and pricing power in natural diamond jewellery?
If the answer is yes, a minority stake through a consortium could be clever. Richemont gets influence over provenance, supply discipline and category messaging without taking full operational risk.
If the answer is no, it is a vanity project. A very expensive one.
That distinction matters because $1 billion is not the real cost. The real cost is what comes after: marketing spend, mine investment, inventory management, political commitments, and years of resisting the temptation to chase volume by cutting prices. De Beers already showed what happens when inventory bought at higher values has to be moved at lower prices: its trading business recorded a $424 million loss in 2025. ([angloamerican.com](https://www.angloamerican.com/~/media/Files/A/Anglo-American-Group-v9/PLC/media/press-release/releases/2026pr/anglo-american-preliminary-results-for-the-year-ended-31-december-2025.pdf?utm_source=openai))
Buying a distressed asset at a low headline valuation is easy. Fixing the behaviour that made it distressed is where the money is won or lost.
What this means for you
Whether you run a startup, buy shares or manage a decent-sized operating business, there is a practical lesson here.
When an upstream asset comes up for sale, do not ask only: “Is it cheap?” Ask these three questions:
1. Does owning it protect a profit pool I already have? Richemont’s jewellery margins are the prize. De Beers would be a defensive asset, not the main event. 2. Can I improve the asset without pretending the market problem does not exist? Lab-grown diamonds are not going away. Any buyer relying on denial is kidding themselves. 3. What must be true for this deal to work in five years? Write it down. For De Beers, it would include restored natural-diamond demand, disciplined supply, credible provenance and partners willing to fund the category rather than merely harvest it.
Use that test tomorrow on your own business. Before buying a supplier, competitor, customer list or distressed brand, identify the economic engine you are actually protecting. Then identify the ugly market fact you would rather ignore.
The best deals do not eliminate reality. They make you stronger because you faced reality before the other bloke did.
Richemont may be doing exactly that. Or it may be paying to preserve a very expensive fairy tale. The next few years will tell us which one.